Characteristics of the two clusters obtained using baseline data of the Be-Giant cohort
| Characteristic . | All (n = 232) . | Cluster A (n = 201) . | Cluster B (n = 31) . | Corrected P* . |
|---|---|---|---|---|
| Gender, % of men | 50.9 | 49.3 | 61.3 | >0.99 |
| Age at disease onset ≥40 years, % | 6.5 | 6.0 | 9.7 | >0.99 |
| Disease symptom duration ≥2 years, % | 53.4 | 60.2 | 9.7 | <0.001 |
| HLA-B27 positivity, % | 67.2 | 71.6 | 38.7 | 0.006 |
| Articular manifestations: | ||||
| Alternating buttock pain, % | 41.4 | 41.8 | 38.7 | >0.99 |
| Peripheral arthritis, % | 19.4 | 8.5 | 90.3 | <0.001 |
| Peripheral enthesitis, % | 9.5 | 5.0 | 38.7 | <0.001 |
| Dactylitis, % | 3.9 | 0 | 9.0 | <0.001 |
| Extra-articular manifestations: | ||||
| Uveitis, % | 12.5 | 12.9 | 9.7 | >0.99 |
| Psoriasis, % | 10.3 | 5.5 | 41.9 | <0.001 |
| Inflammatory bowel disease, % | 4.3 | 4.5 | 3.2 | >0.99 |
| Triggering infection, % | 2.6 | 1.5 | 9.7 | 0.80 |
| Good response to NSAIDs, % | 83.2 | 86.6 | 61.3 | 0.01 |
| Elevated acute phase reactants, % | ||||
| CRP >5 mg/L | 39.2 | 35.3 | 64.5 | 0.05 |
| ESR >10 mm/1h | 40.9 | 36.8 | 67.7 | 0.03 |
| Disease activity: | ||||
| BASDAI, mean (s.d.) | 4.3 (1.9) | 4.1 (1.9) | 5.8 (1.5) | <0.001 |
| ASDAS-CRP, mean (s.d.) | 2.6 (1.0) | 2.5 (0.9) | 3.7 (1.0) | <0.001 |
| Functional outcome | ||||
| BASFI, mean (s.d.) | 2.8 (2.1) | 2.6 (2.0) | 4.2 (2.2) | 0.004 |
| Quality of life | ||||
| BASG, mean (s.d.) | 4.8 (2.8) | 4.5 (2.8) | 6.5 (2.3) | 0.009 |
| Imaging: | ||||
| Radiographic sacroiliitis,a % | 16.4 | 18.9 | 0.0 | 0.21 |
| MRI sacroiliitis,b % | 80.2 | 83.6 | 58.1 | 0.02 |
| ASAS classification criteria fulfilment, % | ||||
| Axial classification criteria, % | 93.5 | 99.5 | 54.8 | <0.001 |
| Peripheral classification criteria, % | 6.5 | 0.5 | 45.2 | <0.001 |
| Characteristic . | All (n = 232) . | Cluster A (n = 201) . | Cluster B (n = 31) . | Corrected P* . |
|---|---|---|---|---|
| Gender, % of men | 50.9 | 49.3 | 61.3 | >0.99 |
| Age at disease onset ≥40 years, % | 6.5 | 6.0 | 9.7 | >0.99 |
| Disease symptom duration ≥2 years, % | 53.4 | 60.2 | 9.7 | <0.001 |
| HLA-B27 positivity, % | 67.2 | 71.6 | 38.7 | 0.006 |
| Articular manifestations: | ||||
| Alternating buttock pain, % | 41.4 | 41.8 | 38.7 | >0.99 |
| Peripheral arthritis, % | 19.4 | 8.5 | 90.3 | <0.001 |
| Peripheral enthesitis, % | 9.5 | 5.0 | 38.7 | <0.001 |
| Dactylitis, % | 3.9 | 0 | 9.0 | <0.001 |
| Extra-articular manifestations: | ||||
| Uveitis, % | 12.5 | 12.9 | 9.7 | >0.99 |
| Psoriasis, % | 10.3 | 5.5 | 41.9 | <0.001 |
| Inflammatory bowel disease, % | 4.3 | 4.5 | 3.2 | >0.99 |
| Triggering infection, % | 2.6 | 1.5 | 9.7 | 0.80 |
| Good response to NSAIDs, % | 83.2 | 86.6 | 61.3 | 0.01 |
| Elevated acute phase reactants, % | ||||
| CRP >5 mg/L | 39.2 | 35.3 | 64.5 | 0.05 |
| ESR >10 mm/1h | 40.9 | 36.8 | 67.7 | 0.03 |
| Disease activity: | ||||
| BASDAI, mean (s.d.) | 4.3 (1.9) | 4.1 (1.9) | 5.8 (1.5) | <0.001 |
| ASDAS-CRP, mean (s.d.) | 2.6 (1.0) | 2.5 (0.9) | 3.7 (1.0) | <0.001 |
| Functional outcome | ||||
| BASFI, mean (s.d.) | 2.8 (2.1) | 2.6 (2.0) | 4.2 (2.2) | 0.004 |
| Quality of life | ||||
| BASG, mean (s.d.) | 4.8 (2.8) | 4.5 (2.8) | 6.5 (2.3) | 0.009 |
| Imaging: | ||||
| Radiographic sacroiliitis,a % | 16.4 | 18.9 | 0.0 | 0.21 |
| MRI sacroiliitis,b % | 80.2 | 83.6 | 58.1 | 0.02 |
| ASAS classification criteria fulfilment, % | ||||
| Axial classification criteria, % | 93.5 | 99.5 | 54.8 | <0.001 |
| Peripheral classification criteria, % | 6.5 | 0.5 | 45.2 | <0.001 |
Refers to radiographic sacroiliitis ≥ grade II bilateral or grade III unilateral.
As defined by the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis.
*After Holm-Bonferroni correction.
ASAS: Assessment of SpondyloArthritis international Society; ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score using CRP; BASG: Bath Ankylosing Spondylitis Global Score.
Characteristics of the two clusters obtained using baseline data of the Be-Giant cohort
| Characteristic . | All (n = 232) . | Cluster A (n = 201) . | Cluster B (n = 31) . | Corrected P* . |
|---|---|---|---|---|
| Gender, % of men | 50.9 | 49.3 | 61.3 | >0.99 |
| Age at disease onset ≥40 years, % | 6.5 | 6.0 | 9.7 | >0.99 |
| Disease symptom duration ≥2 years, % | 53.4 | 60.2 | 9.7 | <0.001 |
| HLA-B27 positivity, % | 67.2 | 71.6 | 38.7 | 0.006 |
| Articular manifestations: | ||||
| Alternating buttock pain, % | 41.4 | 41.8 | 38.7 | >0.99 |
| Peripheral arthritis, % | 19.4 | 8.5 | 90.3 | <0.001 |
| Peripheral enthesitis, % | 9.5 | 5.0 | 38.7 | <0.001 |
| Dactylitis, % | 3.9 | 0 | 9.0 | <0.001 |
| Extra-articular manifestations: | ||||
| Uveitis, % | 12.5 | 12.9 | 9.7 | >0.99 |
| Psoriasis, % | 10.3 | 5.5 | 41.9 | <0.001 |
| Inflammatory bowel disease, % | 4.3 | 4.5 | 3.2 | >0.99 |
| Triggering infection, % | 2.6 | 1.5 | 9.7 | 0.80 |
| Good response to NSAIDs, % | 83.2 | 86.6 | 61.3 | 0.01 |
| Elevated acute phase reactants, % | ||||
| CRP >5 mg/L | 39.2 | 35.3 | 64.5 | 0.05 |
| ESR >10 mm/1h | 40.9 | 36.8 | 67.7 | 0.03 |
| Disease activity: | ||||
| BASDAI, mean (s.d.) | 4.3 (1.9) | 4.1 (1.9) | 5.8 (1.5) | <0.001 |
| ASDAS-CRP, mean (s.d.) | 2.6 (1.0) | 2.5 (0.9) | 3.7 (1.0) | <0.001 |
| Functional outcome | ||||
| BASFI, mean (s.d.) | 2.8 (2.1) | 2.6 (2.0) | 4.2 (2.2) | 0.004 |
| Quality of life | ||||
| BASG, mean (s.d.) | 4.8 (2.8) | 4.5 (2.8) | 6.5 (2.3) | 0.009 |
| Imaging: | ||||
| Radiographic sacroiliitis,a % | 16.4 | 18.9 | 0.0 | 0.21 |
| MRI sacroiliitis,b % | 80.2 | 83.6 | 58.1 | 0.02 |
| ASAS classification criteria fulfilment, % | ||||
| Axial classification criteria, % | 93.5 | 99.5 | 54.8 | <0.001 |
| Peripheral classification criteria, % | 6.5 | 0.5 | 45.2 | <0.001 |
| Characteristic . | All (n = 232) . | Cluster A (n = 201) . | Cluster B (n = 31) . | Corrected P* . |
|---|---|---|---|---|
| Gender, % of men | 50.9 | 49.3 | 61.3 | >0.99 |
| Age at disease onset ≥40 years, % | 6.5 | 6.0 | 9.7 | >0.99 |
| Disease symptom duration ≥2 years, % | 53.4 | 60.2 | 9.7 | <0.001 |
| HLA-B27 positivity, % | 67.2 | 71.6 | 38.7 | 0.006 |
| Articular manifestations: | ||||
| Alternating buttock pain, % | 41.4 | 41.8 | 38.7 | >0.99 |
| Peripheral arthritis, % | 19.4 | 8.5 | 90.3 | <0.001 |
| Peripheral enthesitis, % | 9.5 | 5.0 | 38.7 | <0.001 |
| Dactylitis, % | 3.9 | 0 | 9.0 | <0.001 |
| Extra-articular manifestations: | ||||
| Uveitis, % | 12.5 | 12.9 | 9.7 | >0.99 |
| Psoriasis, % | 10.3 | 5.5 | 41.9 | <0.001 |
| Inflammatory bowel disease, % | 4.3 | 4.5 | 3.2 | >0.99 |
| Triggering infection, % | 2.6 | 1.5 | 9.7 | 0.80 |
| Good response to NSAIDs, % | 83.2 | 86.6 | 61.3 | 0.01 |
| Elevated acute phase reactants, % | ||||
| CRP >5 mg/L | 39.2 | 35.3 | 64.5 | 0.05 |
| ESR >10 mm/1h | 40.9 | 36.8 | 67.7 | 0.03 |
| Disease activity: | ||||
| BASDAI, mean (s.d.) | 4.3 (1.9) | 4.1 (1.9) | 5.8 (1.5) | <0.001 |
| ASDAS-CRP, mean (s.d.) | 2.6 (1.0) | 2.5 (0.9) | 3.7 (1.0) | <0.001 |
| Functional outcome | ||||
| BASFI, mean (s.d.) | 2.8 (2.1) | 2.6 (2.0) | 4.2 (2.2) | 0.004 |
| Quality of life | ||||
| BASG, mean (s.d.) | 4.8 (2.8) | 4.5 (2.8) | 6.5 (2.3) | 0.009 |
| Imaging: | ||||
| Radiographic sacroiliitis,a % | 16.4 | 18.9 | 0.0 | 0.21 |
| MRI sacroiliitis,b % | 80.2 | 83.6 | 58.1 | 0.02 |
| ASAS classification criteria fulfilment, % | ||||
| Axial classification criteria, % | 93.5 | 99.5 | 54.8 | <0.001 |
| Peripheral classification criteria, % | 6.5 | 0.5 | 45.2 | <0.001 |
Refers to radiographic sacroiliitis ≥ grade II bilateral or grade III unilateral.
As defined by the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis.
*After Holm-Bonferroni correction.
ASAS: Assessment of SpondyloArthritis international Society; ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score using CRP; BASG: Bath Ankylosing Spondylitis Global Score.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
